当前位置: 首页 > 期刊 > 《中国现代医生》 > 2021年第16期
编号:669869
CD4+ CD25+ FOXP3+ Treg细胞在高危多发性骨髓瘤治疗中预测复发及治疗意义
http://www.100md.com 2021年9月30日 中国现代医生 2021年第16期
     王晓丽 江妤 曾玉晓 刘永华 章俏雷

    [關键词] CD4+ CD25+ FOXP3+;调节性T淋巴细胞;高危;多发性骨髓瘤;化疗;疗效;复发

    [中图分类号] R733.3? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-9701(2021)16-0032-05

    Significance of CD4+ CD25+ FOXP3+ Treg cells in predicting recurrence and therapeutic effect in treatment of high-risk multiple myeloma

    WANG Xiaoli? ?JIANG Yu? ?ZENG Yuxiao? ?LIU Yonghua? ?ZHANG Qiaolei

    Department of Hematology,Lishui People′s Hospital in Zhejiang Province, Lishui? ?323000, China

    [Abstract] Objective To explore the significance of CD4+ CD25+ FOXP3+ regulatory T lymphocytes (Treg) in predicting recurrence and therapeutic effect in the treatment of high-risk multiple myeloma. Methods A total of 126 patients with high-risk multiple myeloma admitted to our hospital from March 2018 to March 2019 were selected as the case group ......

您现在查看是摘要页,全文长 9007 字符